Epoqe Pharma ApS Financials, key figures and credit report
Gross profit -8 599.2 kDKK FY 2025 +37.3% vs 2024
EBIT -11 005.6 kDKK FY 2025 +34.9% vs 2024
Net debt -43 608.4 kDKK FY 2025 -44.3% vs 2024
Quick ratio 9.8 FY 2025 +2.6 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -17.07 | -19.35 | 1 273.17 | -13 719.78 | -8 599.20 |
| Employee benefit expenses | -1 445.96 | -3 173.44 | -2 406.39 | ||
| EBIT | -17.07 | -19.35 | - 172.79 | -16 893.22 | -11 005.59 |
| Other financial income | 231.49 | 58.50 | |||
| Other financial expenses | -0.96 | -0.43 | -1.46 | -32.99 | -16.88 |
| Pre-tax profit | -18.03 | -19.78 | - 174.25 | -16 694.72 | -10 963.98 |
| Income taxes | 4.35 | 38.34 | 2 750.83 | 1 913.56 | |
| Net earnings | -18.03 | -15.43 | - 135.92 | -13 943.88 | -9 050.41 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | 40.10 | 82.63 | |||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 0.14 | 3.96 | |||
| Current other receivables | 16.46 | 80.44 | 1 794.00 | 764.45 | |
| Current deferred tax assets | 4.35 | 42.69 | 2 789.17 | 4 664.39 | |
| Short term receivables total | 20.81 | 123.27 | 4 583.17 | 5 432.81 | |
| Cash and bank deposits | 145.08 | 2 558.76 | 987.80 | 30 227.33 | 43 634.78 |
| Cash and cash equivalents | 145.08 | 2 558.76 | 987.80 | 30 227.33 | 43 634.78 |
| Balance sheet total (assets) | 145.08 | 2 579.56 | 1 111.06 | 34 850.60 | 49 150.22 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 88.89 | 88.89 | 88.89 | 220.00 | 288.89 |
| Retained earnings | 62.22 | 44.19 | 28.76 | 43 766.04 | 52 906.53 |
| Profit of the financial year | -18.03 | -15.43 | - 135.92 | -13 943.88 | -9 050.41 |
| Shareholders equity total | 133.08 | 117.65 | -18.27 | 30 042.16 | 44 145.00 |
| Non-current accruals and deferred income | 2 443.41 | 859.80 | |||
| Non-current liabilities total | 2 443.41 | 859.80 | |||
| Current loans from credit institutions | 26.34 | ||||
| Current trade creditors | 100.71 | 3 997.26 | 4 317.05 | ||
| Other non-interest bearing current liabilities | 12.00 | 18.50 | 168.82 | 811.18 | 661.83 |
| Current liabilities total | 12.00 | 18.50 | 269.53 | 4 808.44 | 5 005.22 |
| Balance sheet total (liabilities) | 145.08 | 2 579.56 | 1 111.06 | 34 850.60 | 49 150.22 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated